Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.

Related Articles

Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.

Sci Rep. 2016 Nov 18;6:37275

Authors: Monteiro MS, Barros AS, Pinto J, Carvalho M, Pires-Luís AS, Henrique R, Jerónimo C, Bastos ML, Gil AM, Guedes de Pinho P

Abstract
RCC usually develops and progresses asymptomatically and, when detected, it is frequently at advanced stages and metastatic, entailing a dismal prognosis. Therefore, there is an obvious demand for new strategies enabling an earlier diagnosis. The importance of metabolic rearrangements for carcinogenesis unlocked a new approach for cancer research, catalyzing the increased use of metabolomics. The present study aimed the NMR metabolic profiling of RCC in urine samples from a cohort of RCC patients (n = 42) and controls (n = 49). The methodology entailed variable selection of the spectra in tandem with multivariate analysis and validation procedures. The retrieval of a disease signature was preceded by a systematic evaluation of the impacts of subject age, gender, BMI, and smoking habits. The impact of confounders on the urine metabolomics profile of this population is residual compared to that of RCC. A 32-metabolite/resonance signature descriptive of RCC was unveiled, successfully distinguishing RCC patients from controls in principal component analysis. This work demonstrates the value of a systematic metabolomics workflow for the identification of robust urinary metabolic biomarkers of RCC. Future studies should entail the validation of the 32-metabolite/resonance signature found for RCC in independent cohorts, as well as biological validation of the putative hypotheses advanced.

PMID: 27857216 [PubMed - in process]

http://ift.tt/2g83sss